Proving efficacy with a phase 3 is futile while the price remains where it is. It is not marketable. Clinuvel well knows this and that is why VP has been at a standstill for so many years. The price would need to reduce significantly for third party payors to consider reimbursement. I don’t expect Clinuvel will speak much more about VP.
Ann: SCENESSE provides photoprotection in variegate porphyria, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.72 |
Change
-0.100(0.67%) |
Mkt cap ! $737.1M | |||
| Open | High | Low | Value | Volume |
| $14.80 | $14.97 | $14.60 | $600.3K | 40.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 324 | $14.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.75 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |